1 Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA

2 vaccination with a sixteen-week interval between doses

- Alexandra Tauzin^{1,2}, Shang Yu Gong^{1,3}, Guillaume Beaudoin-Bussières^{1,2}, Dani Vézina¹, Romain
 Gasser^{1,2}, Lauriane Nault^{1,2}, Lorie Marchitto^{1,2}, Mehdi Benlarbi¹, Debashree Chatterjee¹, Manon
 Nayrac^{1,2}, Annemarie Laumaea^{1,2}, Jérémie Prévost^{1,2}, Marianne Boutin^{1,2}, Gérémy Sannier^{1,2},
 Alexandre Nicolas^{1,2}, Catherine Bourassa¹, Gabrielle Gendron-Lepage¹, Halima Medjahed¹,
 Guillaume Goyette¹, Yuxia Bo⁴, Josée Perreault⁵, Laurie Gokool¹, Chantal Morrisseau¹, Pascale
 Arlotto¹, Renée Bazin⁵, Mathieu Dubé¹, Gaston De Serres⁶, Nicholas Brousseau⁶, Jonathan
 Richard^{1,2}, Roberta Rovito⁷, Marceline Côté⁴, Cécile Tremblay^{1,2}, Giulia C. Marchetti⁷, Ralf Duerr⁸,
- 10 Valérie Martel-Laferrière^{1,2,*}, Daniel E. Kaufmann^{1,9,*}, and Andrés Finzi^{1,2,3,10,*}
- ¹Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada
- ²Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, H2X
 0A9, Canada
- ³Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada
- ⁴Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and
- 16 Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
- 17 ⁵Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada
- 18 ⁶Institut National de Santé Publique du Québec, Quebec, QC, H2P 1E2, Canada
- ⁷Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
- 21 ⁸Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA
- 22 ⁹Département de Médecine, Université de Montréal, Montreal, QC, H3T 1J4, Canada
- 23 24
- 25 ¹⁰Lead contact
- 26 *Correspondence: valerie.martel-laferriere.med@ssss.gouv.qc.ca (V.M.L.),
- 27 daniel.kaufmann@umontreal.ca (D.E.K.), andres.finzi@umontreal.ca (A.F.)
- 28
- 29 Summary word count: **133**
- 30
- 31 Character count: 42258

It is made available under a CC-BY-NC-ND 4.0 International license .

32 SUMMARY

33 While the standard regimen of the BNT162b2 mRNA vaccine includes two doses 34 administered three weeks apart, some public health authorities decided to space them, raising 35 concerns about vaccine efficacy. Here, we analyzed longitudinal humoral responses including 36 antibody binding, Fc-mediated effector functions and neutralizing activity against the D614G strain but also variants of concern and SARS-CoV-1 in a cohort of SARS-CoV-2 naïve and previously 37 38 infected individuals, with an interval of sixteen weeks between the two doses. While the 39 administration of a second dose to previously infected individuals did not significantly improve 40 humoral responses, we observed a significant increase of humoral responses in naïve individuals after the 16-weeks delayed second shot, achieving similar levels as in previously infected 41 42 individuals. Our results highlight strong vaccine-elicited humoral responses with an extended 43 interval BNT162b2 vaccination for naïve individuals.

44

45 **KEYWORDS:** Coronavirus, COVID-19, SARS-CoV-2, Spike glycoproteins, Delayed mRNA
46 vaccine regimen, Variants of concern, Variants of interest, Humoral responses, Neutralization,
47 ADCC

It is made available under a CC-BY-NC-ND 4.0 International license .

48 INTRODUCTION

49 Since the end of 2019, the etiological agent of the Coronavirus disease 2019 (COVID-19). 50 the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has spread worldwide 51 causing the current pandemic (Dong et al., 2020; World Health Organization). In the last months, 52 several vaccines against SARS-CoV-2 have been approved in many countries, including the 53 Pfizer/BioNtech BNT162b2 mRNA vaccine. This vaccine targets the highly immunogenic trimeric 54 Spike (S) glycoprotein that facilitates SARS-CoV-2 entry into host cells via its receptor-binding 55 domain (RBD) that interacts with angiotensin-converting enzyme 2 (ACE-2) (Hoffmann et al., 56 2020; Walls et al., 2020) and has shown an important vaccine efficacy (Polack et al., 2020; Skowronski and De Serres, 2021). 57

The approved BNT162b2 mRNA vaccine regimen comprises two doses administered 3-4 weeks apart (WHO, 2021). However, at the beginning of the vaccination campaign (Winter/Spring 2021) vaccine scarcity prompted some public health agencies to extend the interval between doses in order to maximize the number of immunized individuals. This strategy was supported by results indicating that a single dose affords ~90% protection starting two weeks post vaccination, concomitant with the detection of some vaccine-elicited immune responses (Baden et al., 2021; Pilishvili, 2021; Polack et al., 2020; Skowronski and De Serres, 2021; Tauzin et al., 2021).

65 The rapid emergence of several variants of concerns (VOCs) and variants of interest (VOIs), which are more transmissible and in some cases more virulent (Allen et al., 2021; Brown et al., 66 67 2021; Davies et al., 2021; Fisman and Tuite, 2021; Pearson et al., 2021) remains a major public 68 health preoccupation as the vaccine campaign advances worldwide. For example, the mutation 69 D614G in the S glycoprotein which appeared very early in the pandemic is now present in almost 70 all circulating strains (Isabel et al., 2020). The B.1.1.7 (Alpha) variant emerged in late 2020 in the 71 United Kingdom and due to its increased affinity for the ACE2 receptor that leads to increased 72 transmissibility (Davies et al., 2021), it became in just a few months a predominant strain

It is made available under a CC-BY-NC-ND 4.0 International license .

73 worldwide (Davies et al., 2021; Prévost et al., 2021; Rambaut et al., 2020). The B.1.351 (Beta) and P.1 (Gamma) variants that first emerged in South Africa and Brazil respectively have largely 74 75 spread and are now circulating in many countries (ECDC, 2021; Tang et al., 2021). The B.1.526 76 (lota) variant first identified in New York in early 2021 (Annavajhala et al., 2021a) is in an upward 77 trajectory in the United States (Annavajhala et al., 2021b). More recently, the B.1.617.2 (Delta) 78 variant which emerged in India and has a high transmissibility is now the dominant strain in several 79 countries (Allen et al., 2021; Dagpunar, 2021). Although several studies have shown that mRNA vaccines protect against severe disease caused by these variants, it has also been shown that 80 81 some of them present resistance to some vaccine-elicited immune responses, notably against 82 neutralizing antibodies (Annavajhala et al., 2021a; Goel et al., 2021a; Planas et al., 2021a; 83 Puranik et al., 2021; Wall et al., 2021; Wang et al., 2021a). Most of these studies were based on 84 the analysis of plasma samples collected from vaccinees following a short (3-4 weeks) interval 85 between doses. Little is known about vaccine-elicited immune responses with longer dose 86 intervals. Here, we characterized vaccine-elicited humoral responses in a cohort of SARS-CoV-2 87 naïve and previously infected individuals that received the two doses with an extended interval of 88 sixteen weeks.

89

It is made available under a CC-BY-NC-ND 4.0 International license .

91 RESULTS

92 We analyzed the longitudinal humoral responses after vaccination with the BNT162b2 93 mRNA vaccine in blood samples, with an interval of around 16 weeks between the two doses 94 (median [range]: 111 days [90–134 days]). The cohort included 22 SARS-CoV-2 naïve and 21 95 previously infected (PI) donors tested SARS-CoV-2 positive by nasopharyngeal swab PCR around 9 months before their first dose (median [range]: 280 days [116-326 days]). In the cohort 96 97 of PI individuals, 10 donors did not receive the second injection, leaving 11 PI donors with two doses. The blood samples were collected at different time points: prior the first dose of vaccine 98 99 (V0), three weeks (V1, median [range]: 21 days [13-28 days]) and three months (V2, median 100 [range]: 85 days [73–104 days]) after the first dose of vaccine and three weeks after the second 101 vaccine injection (V3, median [range]: 21 days [13-42 days]). Data collected at V0 and V1 have 102 been previously described (Tauzin et al., 2021). Basic demographic characteristics of the cohorts 103 and detailed vaccination timepoints are summarized in Table 1 and Figure 1A.

104

105 Elicitation of SARS-CoV-2 antibodies against the full Spike and its receptor-binding 106 domain

To evaluate vaccine responses in SARS-CoV-2 naïve and PI individuals, we first 107 108 measured the presence of SARS-CoV-2-specific antibodies (Abs) (IgG, IgM, IgA) recognizing the 109 receptor-binding domain (Figure 1B-E) using an ELISA RBD assay or the native full-length S 110 glycoprotein expressed at the cell surface (Figure 1F-I) using a cell-based ELISA assay. Both 111 assays have been previously described (Anand et al., 2021; Beaudoin-Bussières et al., 2020; 112 Prévost et al., 2020). Prior to vaccination (V0), no SARS-CoV-2 specific Abs were detectable in 113 SARS-CoV-2 naïve individuals, except for anti-Spike IgM (31.8% seropositivity) which are likely 114 to be cross-reactive antibodies against the S2 subunit (Fraley et al., 2021; Hicks et al., 2020; Ng 115 et al., 2020). SARS-CoV-2 PI individuals still had detectable Abs several months post-symptoms

It is made available under a CC-BY-NC-ND 4.0 International license .

116 onset, especially IgG, in agreement with previous observations (Anand et al., 2021; Dan et al., 2021; Tauzin et al., 2021; Wang et al., 2021b). For both groups, the first dose of vaccine induced 117 118 a significant increase of total immunoglobulins (Igs) recognizing the RBD or the Spike protein 119 three weeks post-vaccine (V1), with a significantly higher response for the PI group (Figure 1B-120 I). At V2 (i.e., 12 weeks post vaccination), while anti-Spike total Ig levels remained stable, we 121 observed a decrease in anti-RBD total Ig levels in both groups, with the exception of some naïve 122 donors where we observed an increase. We did not detect Abs recognizing the N protein for 123 these donors (not shown), suggesting that they had not been infected between the two doses. 124 This increase could therefore be linked to a delayed response or affinity maturation of the 125 antibodies in the germinal center between V1 and V2. The second dose, which was administered 126 ~16 weeks after the first one, strongly boosted the induction of anti-RBD Igs in the SARS-CoV-2 127 naïve group, particularly IgG and IgA which reached higher levels, albeit not statistically 128 significant, than those measured three weeks after the first dose (Figure 1D and E). For the PI 129 group, the second dose also led to an increase in the level of total anti-RBD Igs that reached 130 similar levels than after the first dose. Of note, the second dose in the naïve group elicited anti-131 RBD IgG levels that reached the same levels than in the PI group receiving two doses and 132 significantly higher than PI receiving only one (Figure 1D). Similar patterns of responses were 133 observed when we measured the level of Abs recognizing the full-length S glycoprotein (Figure 134 1F-I).

135

136 Recognition of SARS-CoV-2 Spike variants and other Betacoronaviruses

The BNT162b2 mRNA vaccine has been developed against the original Wuhan strain. However, SARS-CoV-2 is evolving, and many variants have emerged and spread rapidly worldwide. Some harbor specific mutations in S that are associated with increased transmissibility and/or immune evasion (Davies et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021). Here, we evaluated the ability of Abs elicited by the Pfizer/BioNTech vaccine to recognize

It is made available under a CC-BY-NC-ND 4.0 International license .

different S proteins of VOCs (B.1.1.7, B.1.351, P.1 and B.1.612.2) and the VOI B.1.526 expressed
at the cell surface of 293T cells by flow cytometry, using a method we have previously described
(Figure 2, S1) (Gong et al., 2021; Prévost et al., 2020; Tauzin et al., 2021).

145 As expected, none of the SARS-CoV-2 naïve plasma samples collected at V0 were able to recognize the SARS-CoV-2 S (D614G) or any of the variants tested here (B.1.1.7, B.1.351, 146 147 B.1.617.2, P.1, B.1.526) (Figure 2A-F). In contrast, plasma from PI individuals recognized all 148 tested SARS-CoV-2 variants at V0 (Figure 2A-F, S1). The first dose of vaccine strongly enhanced 149 the recognition of the full D614G S and all the tested variants in both groups (Figure 2A-F). Three 150 months after the first dose, the recognition slightly decreased but not significantly. As expected, 151 the second dose strongly increased recognition of all VOC Spikes in the naïve group and reached 152 levels that where significantly higher than after the first dose. In contrast, for the PI group, the 153 second dose did not result in a better recognition than after the first dose. Of note, we observed 154 no significant differences at V3 between PI individuals who received one or two doses, despite a 155 shorter period since the last dose for PI individuals who received two doses. The recognition of 156 all VOCs was slightly lower at V3 by the naïve group compared to the PI that received two doses 157 (Figure 2A-F). When we compared Spike recognition between the SARS-CoV-2 variants, we 158 observed that plasma from PI individuals before vaccination recognized less efficiently the 159 different S variants compared to the D614G S, with the exception of B.1.1.7 S (Figure S1A). After 160 the first and second dose, only B.1.351 and B.1.617.2 S were less efficiently recognized by 161 plasmas from PI individuals (Figure S1B-D). For naïve individuals, even if the vaccination strongly 162 increased the recognition of every VOC Spike tested, we observed that plasmas recognized the 163 different SARS-CoV-2 variants less efficiently compared to D614G S except for the B.1.1.7 S 164 (Figure S1).

165 We also evaluated whether vaccination elicited Abs that were able to recognize S 166 glycoproteins from endemic human *Betacoronaviruses*, (HCoV-OC43 and HCoV-HKU1).

It is made available under a CC-BY-NC-ND 4.0 International license .

Interestingly, we observed that the first but not the second dose enhanced the recognition of HCoV-HKU1 S in the naïve group (Figure 2H). Moreover, we observed that plasma from PI donors better recognized HCoV-HKU1 S than plasma from naïve donors at every time point studied, suggesting that natural infection induced cross reactive Abs more efficiently than vaccination. In contrast, both doses did not significantly improve the recognition of HCoV-OC43 S (Figure 2G).

172 We then evaluated the capacity of the different plasma samples to bind S from highly 173 pathogenic human coronaviruses (SARS-CoV-1 and MERS-CoV). We observed that PI 174 individuals did not have Abs able to recognize MERS-CoV S before vaccination, in contrast to 175 SARS-CoV-1 S (Figure 2I-J). This is likely related the closer genetic relationship between SARS-176 CoV-2 and SARS-CoV-1 than MERS-CoV (Rabaan et al., 2020; Sarkar et al., 2021). As 177 previously observed (Tauzin et al., 2021), the first dose of vaccine significantly increased the 178 recognition of the MERS-CoV S (Figure 2I) in both groups. However, the second dose did not 179 enhance this recognition. On the other hand, both vaccine doses significantly increased the level 180 of recognition of the SARS-CoV-1 Spike in the naïve group (Figure 2J). In the PI group, only the 181 first dose significantly improved the recognition. We note that the long interval between doses 182 brings SARS-CoV-2 naïve individuals to recognize the different variant Spikes and related HCoV 183 to the same extent than previously-infected individuals.

184

185 Functional activities of vaccine-elicited antibodies

We (Tauzin et al., 2021) and others (Collier et al., 2021; Goel et al., 2021b; Planas et al., 2021b; Sahin et al., 2020) reported that three weeks post first Pfizer/BioNTech dose, SARS-CoV-2 S specific antibodies with weak neutralizing properties are elicited. Nevertheless, these Abs present robust Fc-mediated effector functions as measured by their capacity to mediate antibodydependent cellular cytotoxicity (ADCC) (Tauzin et al., 2021). To obtain a better understanding of this functional property over time, we tested all plasma samples with our previously reported

192 ADCC assay (Anand et al., 2021; Beaudoin-Bussieres et al., 2021; Tauzin et al., 2021; Ullah et 193 al., 2021). As expected, and in agreement with the absence of SARS-CoV-2 S specific antibodies 194 at baseline, no ADCC activity was observed for the naïve group before vaccination (Figure 3A). 195 Plasma from the PI group maintained some levels of ADCC activity before vaccination, in 196 agreement with a longitudinal study following immune responses in convalescent donors (Anand 197 et al., 2021). Three weeks after the first dose, ADCC activity was elicited in both groups, but 198 significantly higher in the PI group. A decline in ADCC responses was observed in both groups 199 nine weeks after V1 (V2, i.e., 12 weeks post vaccination). The second dose strongly boosted 200 ADCC activity in the naïve group but remained stable for the PI groups. We noted that the levels 201 of ADCC activity were significantly higher in the PI group at all timepoints (Figure 3A).

202 Neutralizing activity in plasma is thought to play an important role in vaccine efficacy 203 (Jackson et al., 2020; Muruato et al., 2020; Polack et al., 2020). Accordingly, it has been recently 204 identified as an immune-correlate of protection in the mRNA-1273 COVID-19 vaccine efficacy trial 205 (Gilbert et al., 2021). To evaluate the vaccine neutralizing response over time, we measured the 206 capacity of plasma samples to neutralize pseudoviral particles carrying the SARS-CoV-2 S 207 D614G glycoprotein (Figure 3B). We did not detect a significant increase in neutralization in 208 plasma isolated three weeks post vaccination of the naïve group, as previously described (Tauzin 209 et al., 2021). Interestingly, nine weeks later (V2, i.e., 12 weeks post vaccination), we observed 210 increased neutralizing activity in a few donors (Figure 3B). All donors presented a significant 211 increase in neutralizing activity three weeks after the second dose. Importantly, the level of 212 neutralizing activity of double vaccinated naïve individuals reached the same levels than in the PI 213 group after one or two doses. In this latter group (PI), we measured low neutralizing activity before 214 vaccination, consistent with remaining neutralizing activity in convalescent donors after several 215 months post symptoms onset (Anand et al., 2021; Gaebler et al., 2021; Tauzin et al., 2021). As 216 previously described, the first dose strongly increased neutralization activity (Stamatatos et al., 217 2021; Tauzin et al., 2021), but this activity significantly decreased a few weeks after (V2, i.e., 12

It is made available under a CC-BY-NC-ND 4.0 International license .

weeks post vaccination). The second dose boosted the neutralizing activity to the levels reached three weeks after the first dose. No difference in neutralization was observed between V1 and V3 for PI individuals. In contrast, in naïve individuals we observed a significantly higher neutralizing activity after the second dose compared to the first one (Figure 3B). Thus, while one dose is required to reach maximum neutralization activity in PI individuals, this activity decays over time and a second dose is required to bring back its maximum potential. On the other hand, naïve individuals requires both doses to achieve the same level of PI vaccinated individuals.

225

226 Neutralizing activity against variants of concern

227 SARS-CoV-2 is evolving, and variants of concern are emerging globally (Davies et al., 228 2020; Prévost and Finzi, 2021; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021). To 229 evaluate whether the long interval between the two doses impacted the capacity of vaccine-230 elicited antibodies to neutralize VOCs and VOI, we measured the neutralizing activity against 231 pseudoviral particles bearing selected variant Spikes (Figure 4, S2). For all the variants tested, 232 we observed a similar pattern than for the D614G S, with neutralizing Abs mainly induced after 233 the second dose in the naïve group (Figure 4A-E). Previously-infected individuals followed a 234 different pattern. While their plasma had some levels of neutralizing activity at baseline, it gained 235 potency and breadth after the first dose. A second dose did not further enhance this activity. 236 Accordingly, we found no significant differences in neutralizing activity in plasma from PIs that 237 received one or two doses measured at V3 (i.e., week 19).

We also noted that, with the exception of B.1.1.7, plasma from the PI group prior to vaccination (V0) neutralized less efficiently all pseudoviral particles bearing variant Spikes compared to the D614G (Figure S2A). Importantly, both doses boosted the neutralizing activity against all variants and SARS-CoV-1 Spike at V3 (Figure S2D).

It is made available under a CC-BY-NC-ND 4.0 International license .

242 Vaccination of PI individuals was shown to increase neutralization against pseudoviral 243 particles bearing the SARS-CoV-1 Spike (Stamatatos et al., 2021; Tauzin et al., 2021). This Spike 244 is used as a representative variant that is even more dissimilar to the vaccine, which was based 245 on the ancestral Wuhan strain. While only one dose was sufficient to provide SARS-CoV-1 246 neutralizing capacity in PI individuals, two were required in naïve individuals. Remarkably, plasma 247 from naïve individuals reached the same level of neutralizing activity against pseudoviral particles 248 bearing the SARS-CoV-1 Spike than PI. Thus, suggesting that the delayed boosting in naïve 249 individuals allows antibody maturation resulting in enhanced breath (Figure 4F).

250

251 Humoral responses in individuals receiving a short dose interval regimen

252 We also analyzed the humoral responses of 11 SARS-CoV-2 naïve donors from a 253 separate cohort who received their two doses of Pfizer/BioNTech mRNA vaccine three weeks 254 apart (median [range]: 21 days [21-21 days]) (Table 1 and Figure 5A). Unfortunately, for these 255 donors, blood samples were only collected at baseline (V0, prior to vaccination) and 22 weeks 256 (median [range]: 152 days [147–158 days]) after the first dose, thus precluding a direct side-by-257 side comparison of humoral responses with our cohort of naïve individuals that received the two 258 doses 16 weeks apart. In other words, the V3 of individuals receiving the second dose following 259 a short interval regimen was collected ~19 weeks post boost whereas the V3 of those with a long 260 interval corresponds to 3 weeks post boost (Figure 1A and 5A). While not a perfect match, we 261 decided to compare the humoral responses of short interval vaccinated individuals with those 262 from PI that received a single dose since their V3 was collected ~19 weeks post vaccination. 263 While we observed no significant differences in total Ig recognizing the RBD or the full S (Figure 264 5B and F), single dose PI individuals had more anti-RBD IgG and IgA than naïve donors who 265 received their two doses 3 weeks apart (Figure 5D and E). Despite minor differences in the overall 266 amount of anti-RBD or anti-Spike Abs, we observed major differences related to their capacity to 267 recognize the full Spike. Plasma from short interval vaccinated individuals was significantly less

It is made available under a CC-BY-NC-ND 4.0 International license .

268	efficient at recognizing the D614G S and all other S variants tested (Figure 5J). Major differences
269	were also observed, particularly related to their capacity to mediate ADCC (Figure 5K) or
270	neutralize pseudoviral particles bearing D614G or any of the variant Spike tested (Figure 5L).
271	Indeed, the naïve donors with a short interval between doses had a very low ID_{50} against all the
272	variant tested ~19 weeks after the vaccine series. No neutralizing activity against SARS-CoV-1
273	was observed (Figure 5L). In contrast, plasmas from PI individual who received just one dose
274	presented neutralizing activity against all the SARS-CoV-2 variants but also the SARS-CoV-1
275	pseudoviruses (Figure 5L).
276	
277	
278	Integrated analysis of vaccine responses elicited with a sixteen-weeks interval between
279	doses
280	When studying the network of pairwise correlations among all studied immune variables
281	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after
281 282	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses,
281 282 283	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon 1 st vaccination slightly collapsed until the
281 282 283 284	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon 1 st vaccination slightly collapsed until the delayed 2 nd vaccination triggered a dense network of positive correlations involving binding
281 282 283 284 285	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon 1 st vaccination slightly collapsed until the delayed 2 nd vaccination triggered a dense network of positive correlations involving binding neutralization responses against several SARS-CoV-2 variants and SARS-CoV-1 (but hardly
281 282 283 284 285 286	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon 1 st vaccination slightly collapsed until the delayed 2 nd vaccination triggered a dense network of positive correlations involving binding neutralization responses against several SARS-CoV-2 variants and SARS-CoV-1 (but hardly OC43, HKU1, or MERS spike), ADCC, and memory B cell responses.
281 282 283 284 285 286 287	in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after the first vaccine dose with focused clusters among binding and neutralization responses, respectively. Over time, the network induced upon 1 st vaccination slightly collapsed until the delayed 2 nd vaccination triggered a dense network of positive correlations involving binding neutralization responses against several SARS-CoV-2 variants and SARS-CoV-1 (but hardly OC43, HKU1, or MERS spike), ADCC, and memory B cell responses.

It is made available under a CC-BY-NC-ND 4.0 International license .

290 **DISCUSSION**

291 The approved regimen of the BNT162b2 mRNA vaccine is the administration of two doses within a short interval of 3-4 weeks. Despite the rapid approval of different vaccine platforms, 292 293 generating the required doses to immunize the world population represents a daunting task 294 (Moore and Klasse, 2020). Confronted to vaccine scarcity, some jurisdictions decided to increase 295 the interval between doses in order to increase the number of immunized individuals. This 296 decision led to concerns about vaccine efficacy, notably against emergent variants rapidly 297 spreading worldwide and more resistant notably against neutralizing Abs induced by vaccination 298 (Annavajhala et al., 2021a; Planas et al., 2021a; Puranik et al., 2021; Wall et al., 2021; Wang et 299 al., 2021a). Here, we measured the humoral responses of SARS-CoV-2 naïve and SARS-CoV-2 300 PI individuals who received their two doses sixteen weeks apart.

301 We observed that in the SARS-CoV-2 naïve group the BNT162b2 mRNA vaccine elicited 302 antibodies with weak neutralizing activity but strong Fc-mediated functions three weeks after the 303 first dose (Tauzin et al., 2021). These responses declined in the following weeks in the absence 304 of a boost. However, administration of the second dose sixteen weeks later strongly enhanced 305 these responses, notably neutralization against some VOCs/VOIs and even the divergent SARS-306 CoV-1. Therefore, despite initial concerns, the long interval between the doses did not result in 307 poor immune responses, in agreement with recent findings (Parry et al., 2021). The idea behind 308 the strategy of delaying the second dose was to provide some level of immunity to a larger number 309 of individuals than if the second dose would have been saved to administer them three weeks 310 later. However, despite the immunological benefits of increasing the interval between the two 311 doses, this also increases the probability of being infected before the boost.

Several studies have shown that vaccination of previously-infected individuals elicits strong cellular and humoral responses (Efrati et al., 2021; Lozano-Ojalvo et al., 2021; Stamatatos et al., 2021; Tauzin et al., 2021; Urbanowicz et al., 2021). In agreement with these studies, we

It is made available under a CC-BY-NC-ND 4.0 International license .

315 found that vaccination of these individuals resulted in the induction of strong humoral responses. 316 These responses remained relatively stable over time. We noticed that the second dose did not 317 result in a significant enhancement of these responses, even with a long interval of 16 weeks 318 between doses. Our results demonstrate that, while the second dose boosts the humoral 319 response, PI individuals reach their peak of immunity after the first dose. Altogether, these results 320 suggest that a second dose for PI individuals might be delayed beyond sixteen weeks after the 321 first dose. These observations are in agreement with recent studies showing that PI individuals 322 had maximal humoral and CD4+ and CD8+ T cell responses after the first dose of an mRNA 323 vaccine; the second did not strongly boost these responses (Goel et al., 2021a; Lozano-Ojalvo et 324 al., 2021; Painter et al., 2021).

325 In contrast, here we show that a delayed second vaccine boost in naïve individuals 326 significantly enhances several immune responses and tightens the network of linear correlations 327 among those. The involved immune variables were humoral and cellular responses directed 328 against SARS-CoV-2, including diverse variants, and SARS-CoV-1, but not or marginally against 329 OC43, HKU1, or MERS. Thus, the potency, quality, and concerted triggering of immune 330 responses appear enhanced in naïve individuals vaccinated with a prolonged interval of 16 weeks 331 between first and second shot, comparable to those obtained after vaccination of previously 332 infected individuals.

333

We also analyzed humoral responses in a cohort of naïve donors who received their two doses according to the approved three-week interval. Plasma collected ~19 weeks post second dose, had poor humoral activities with low neutralizing activity against D614G strain and even weaker activity against some VOCs/VOIs including B.1.617.2. These results are in agreement with recent studies showing that circulating antibody levels and neutralizing activity decline over

It is made available under a CC-BY-NC-ND 4.0 International license .

time (Doria-Rose et al., 2021; Goel et al., 2021a). In contrast, we observed that PI individuals who
received one dose had better responses 19 weeks after their dose.

341

342 Field effectiveness studies in Israël and the USA, where a short interval between doses is 343 recommended, suggest waning protection of the BNT162b2 mRNA vaccine series against non-344 severe disease after a period of approximately 5 months (CDC, 2021; Goldberg et al., 2021; JCVI, 345 2021; Tartof et al., 2021). However, SARS-CoV-2 specific memory B cell and CD4+ T cell 346 responses remains stable for the following 6 months, likely protecting from severe disease (Goel 347 et al., 2021a). Whether the same kind of waning will be observed with an extended schedule 348 remains to be evaluated. It will be of critical importance to monitor immune responses and vaccine 349 effectiveness of these extended schedules over time. If the strong humoral response seen with 350 this extended schedule is longer-lasting than immune responses following the authorized 351 schedule, the need of a third dose might be delayed and this could have significant implications 352 regarding control of COVID-19.

353

354 To end this pandemic, it will be necessary to rapidly vaccinate the world's population, 355 including in countries where vaccines are poorly available. The research community around the 356 globe rapidly generated a wealth of data related to vaccine-elicited immune responses and 357 vaccine efficacy. Globally, these results suggest that the current vaccine strategy that was initially 358 deployed could be improved. Our results suggest that modifying the interval at which the two 359 doses are administered might be an important factor to take into account. It will be important to 360 keep in mind that a fine balance needs to be achieved in order to avoid infection between the two 361 doses and at the same time provide sufficient time to elicit optimal humoral responses.

- 362
- 363

It is made available under a CC-BY-NC-ND 4.0 International license .

364 ACKNOWLEDGMENTS

365 The authors are grateful to the donors who participated in this study. The authors thank 366 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. Stefan 367 Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 and 368 SARS-CoV-1 S glycoproteins and Dr. M. Gordon Joyce (U.S. MHRP) for the monoclonal antibody 369 CR3022. This work was supported by le Ministère de l'Économie et de l'Innovation du Québec, 370 Programme de soutien aux organismes de recherche et d'innovation to A.F. and by the Fondation 371 du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR 372 operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 373 for SARS-CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the 374 Canada Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented 375 was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration 376 with Fonds de Recherche du Québec Santé (FRQS) to A.F. This work was also partially supported 377 by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 378 Variant Research to MC. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. 379 RCHS0235 950-232424. MC is a Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS 380 381 Merit Research Scholar. G.B.B. is the recipient of a FRQS PhD fellowship and J.P. is the recipient 382 of a CIHR PhD fellowship. G.S. is supported by a scholarship from the Department of 383 Microbiologie, Infectiologie et Immunology of Université de Montréal. R.G. and A.L. were 384 supported by MITACS Accélération postdoctoral fellowships. The funders had no role in study 385 design, data collection and analysis, decision to publish, or preparation of the manuscript. We 386 declare no competing interests.

387

It is made available under a CC-BY-NC-ND 4.0 International license .

389 AUTHOR CONTRIBUTIONS

390	A.T. and A.F. conceived the study. A.T., G.B.B., R.G., J.Prévost, M.N., J.R., D.E.K., and
391	A.F. designed experimental approaches. A.T., S.Y.G., G.B.B., D.V., R.G., L.N., L.M., M.Benlarbi,
392	D.C., M.N., A.L., J.Prévost, M.Boutin, G.S., A.N., C.B., Y.B., M.D., D.E.K., and A.F. performed,
393	analyzed, and interpreted the experiments. A.T. and R.D. performed statistical analysis. S.Y.G.,
394	G.B.B., A.L., J.Prévost, G.G.L., H.M., G.G., Y.B., J.R., M.C and A.F. contributed unique reagents.
395	J.Perreault, L.G., C.M., P.A., R.B., R.R., G.C.M., C.T. and V.ML. collected and provided clinical
396	samples. G.D.S., and N.B. provided scientific input related to VOC and vaccine efficacy. A.T., and
397	A.F. wrote the manuscript with inputs from others. Every author has read, edited, and approved
398	the final manuscript.
399	
400	DECLARATION OF INTERESTS

401 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

403 FIGURE LEGENDS

404 Figure 1. Elicitation of RBD- and Spike-specific antibodies in SARS-CoV-2 naïve and 405 previously-infected individuals.

406 (A) SARS-CoV-2 vaccine cohort design. (B-E) Indirect ELISA was performed by incubating plasma samples from naïve and PI donors collected at V0, V1, V2 and V3 with recombinant 407 408 SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated (B) anti-409 human IgM+IgG+IgA (C) anti-human IgM, (D) anti-human IgG, or (E) anti-human IgA. Relative 410 light unit (RLU) values obtained with BSA (negative control) were subtracted and further 411 normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. (F-I) Cell-412 based ELISA was performed by incubating plasma samples from naïve and PI donors collected 413 at V0, V1, V2 and V3 with HOS cells expressing full-length SARS-CoV-2 S. Anti-S Ab binding 414 was detected using HRP-conjugated (F) anti-human IgM+IgG+IgA (G) anti-human IgM, (H) anti-415 human IgG, or (I) anti-human IgA. RLU values obtained with parental HOS (negative control) were 416 subtracted and further normalized to the signal obtained with the CR3022 mAb present in each 417 plate. Naïve and PI donors with a long interval between the two doses are represented by red 418 and black points respectively and PI donors who received just one dose by blue points. (Left 419 panels) Each curve represents the normalized RLUs obtained with the plasma of one donor at 420 every time point. Mean of each group is represented by a bold line. The time of vaccine dose 421 injections is indicated by black triangles. (Right panels) Plasma samples were grouped in 422 different time points (V0, V1, V2 and V3). Undetectable measures are represented as white 423 symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant). 424

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Binding of vaccine-elicited antibodies to SARS-CoV-2 Spike variants and other Betacoronaviruses.

428 293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants 429 and other human Betacoronavirus Spike and stained with the CV3-25 Ab or with plasma from 430 naïve or PI donors collected at V0, V1, V2 and V3 and analyzed by flow cytometry. The values 431 represent the median fluorescence intensities (MFI) (G,H and I) or the MFI normalized by CV3-432 25 Ab binding (A-F, J). Naïve and PI donors with a long interval between the two doses are represented by red and black points respectively and PI donors who received just one dose by 433 434 blue points. (Left panels) Each curve represents the MFI or the normalized MFIs obtained with 435 the plasma of one donor at every time point. Mean of each group is represented by a bold line. 436 The time of vaccine dose injections is indicated by black triangles. (Right panels) Plasma 437 samples were grouped in different time points (V0, V1, V2 and V3). Undetectable measures are 438 represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant). 439

440

441 Figure 3. Fc-effector function and neutralization activities in SARS-CoV-2 naïve and 442 previously-infected individuals before and after Pfizer/BioNTech mRNA vaccine.

(A) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-Spike cells and were used
as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based
ADCC assay. (B) Neutralizing activity was measured by incubating pseudoviruses bearing SARSCoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2
cells. Neutralization half maximal inhibitory serum dilution (ID₅₀) values were determined using a
normalized non-linear regression using GraphPad Prism software. Naïve and PI donors with a
long interval between the two doses are represented by red and black points respectively and PI

It is made available under a CC-BY-NC-ND 4.0 International license .

donors who received just one dose by blue points. (Left panels) Each curve represents the values obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. The time of vaccine dose injections is indicated by black triangles. (**Right panels**) Plasma samples were grouped in different time points (V0, V1, V2 and V3). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant).

456

457 **Figure 4. Neutralization activities against different SARS-CoV-2 VOCs and SARS-CoV-1 in** 458 **naïve and previously-infected individuals before and after Pfizer/BioNTech mRNA vaccine.**

459 Neutralizing activity was measured by incubating pseudoviruses bearing the indicated SARS-460 CoV-2 VOCs or SARS-CoV-1 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C 461 before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID₅₀) 462 values were determined using a normalized non-linear regression using GraphPad Prism 463 software. Naïve and PI donors with a long interval between the two doses are represented by red 464 and black points respectively and PI donors who received just one dose by blue points. (Left 465 panels) Each curve represents the values obtained with the plasma of one donor at every time 466 point. Mean of each group is represented by a bold line. The time of vaccine dose injections is 467 indicated by black triangles. (Right panels) Plasma samples were grouped in different time points 468 (V0, V1, V2 and V3). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; 469 470 **** P < 0.0001; ns, non-significant).

471

472 Figure 5. Humoral responses in SARS-CoV-2 naïve individuals that received a short dose
473 interval versus previously-infected individuals receiving only one dose.

474 (A) SARS-CoV-2 vaccine cohort design. (B-E) Indirect ELISA was performed by incubating 475 plasma samples from naïve and PI donors collected at V3 with recombinant SARS-CoV-2 RBD 476 protein. Anti-RBD Ab binding was detected using HRP-conjugated (B) anti-human IgM+IgG+IgA 477 (C) anti-human IgM, (D) anti-human IgG, or (E) anti-human IgA. Relative light unit (RLU) values 478 obtained with BSA (negative control) were subtracted and further normalized to the signal 479 obtained with the anti-RBD CR3022 mAb present in each plate. (F-I) Cell-based ELISA was 480 performed by incubating plasma samples from naïve and PI donors collected at V3 with HOS 481 cells expressing full-length SARS-CoV-2 S. Anti-S Ab binding was detected using HRP-482 conjugated (F) anti-human IgM+IgG+IgA (G) anti-human IgM, (H) anti-human IgG, or (I) anti-483 human IgA. RLU values obtained with parental HOS (negative control) were subtracted and 484 further normalized to the signal obtained with the CR3022 mAb present in each plate. (J) 293T 485 cells were transfected with the indicated full-length S and stained with the CV3-25 Ab or with 486 plasma from naïve or PI donors collected at V3 and analyzed by flow cytometry. The values 487 represent the MFI normalized by CV3-25 Ab binding. (K) CEM.NKr parental cells were mixed at 488 a 1:1 ratio with CEM.NKr-Spike cells and were used as target cells. PBMCs from uninfected 489 donors were used as effector cells in a FACS-based ADCC assay. (L) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins or SARS-CoV-1 S 490 491 glycoprotein, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. 492 Neutralization half maximal inhibitory serum dilution (ID_{50}) values were determined using a 493 normalized non-linear regression using GraphPad Prism software. PI donors who received one 494 dose are represented by blue points and naïve donors with a short interval between the two doses 495 by green points. Plasma samples were grouped at V3. Undetectable measures are represented 496 as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (* P < 497 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant).

498

It is made available under a CC-BY-NC-ND 4.0 International license .

499 Figure 6. Mesh correlations of humoral response parameters in SARS-CoV-2 naïve 500 individuals before and after Pfizer/BioNTech mRNA vaccine.

- 501 Edge bundling correlation plots where red and blue edges represent positive and negative 502 correlations between connected parameters, respectively. Only significant correlations (p < 0.05, 503 Spearman rank test) are displayed. Nodes are color coded based on the grouping of parameters 504 according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge 505 bundling plots are shown for correlation analyses using four different datasets; i.e., SARS-CoV-2 506 naive individuals at V0, V1, V2 and V3 respectively. 507

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts

		SARS-CoV-2 Naïve		SARS-CoV-2 Previously infected		
		Two doses Short interval (n=11)	Two doses Long interval (n=22)	Two doses Long interval (n=11)	One dose (n=10)	Entire cohort (n=21)
Age		40 (30-52)	51 (21-59)	44 (39-65)	56 (23-65)	47 (23-65)
Condor	Male (n)	3	7	7	2	9
Gender	Female (n)	8	15	4	8	12
Days between symptom onset and the 1 st dose ^a		N/A	N/A	274 (185-321)	280 (116-326)	280 (116-326)
Days between the 1 st and 2 nd dose ^a		21 (21-21)	112 (108-120)	111 (90-134)	N/A	N/A
Days between V0 and the 1 st dose ^a		0 (0-7)	2 (0-49)	23 (0-95)	13 (1-73)	17 (1-95)
Days between the 1 st dose and V1 ^a		N/A	21 (16-28)	20 (17-25)	20 (13-21)	20 (13-25)
Days between the 1 st dose and V2 ^a		N/A	83 (73-92)	89 (83-97)	90 (84-104)	90 (83-104)
Days between V2 and the 2 nd dose ^a		N/A	28 (21-38)	23 (2-42)	N/A	N/A
Days betw dose a	veen the 1 st nd V3 ^a	152 (147-158)	134 (123-144)	138 (103-152)	134 (120-146)	137 (103-152)
Days bet 2 nd dose	tween the and V3 ^a	131 (126-137)	21 (14-34)	21 (13-42)	N/A	N/A

510

509

511 ^a Values displayed are medians, with ranges in parentheses.

It is made available under a CC-BY-NC-ND 4.0 International license .

512	STAR METHODS
513	
514	RESOURCE AVAILABILITY
515	
516	Lead contact
517	Further information and requests for resources and reagents should be directed to and will be
518	fulfilled by the lead contact, Andrés Finzi (andres.finzi@umontreal.ca)
519	
520	Materials availability
521	All unique reagents generated during this study are available from the Lead contact without
522	restriction.
523	
524	Data and code availability
525	The published article includes all datasets generated and analyzed for this study. Further
526	information and requests for resources and reagents should be directed to and will be fulfilled by
527	the Lead Contact Author (andres.finzi@umontreal.ca).
528	
529	EXPERIMENTAL MODEL AND SUBJECT DETAILS
530	
531	Ethics Statement
532	All work was conducted in accordance with the Declaration of Helsinki in terms of informed
533	consent and approval by an appropriate institutional board. Blood samples were obtained from
534	donors who consented to participate in this research project at Centre Hospitalier de l'Université
535	de Montréal (CHUM) and at Azienda Socio-Sanitaria Territoriale (ASST) Santi Paolo e Carlo,
536	Milan. The study was approved by the respective Institutional Review Boards (no. 19.381 at
537	CHUM and no. 2020/ST/049 at ASST Santi Paolo et Carlo). Plasma and PBMCs were isolated

It is made available under a CC-BY-NC-ND 4.0 International license .

538 by centrifugation and Ficoll gradient, and samples stored at -80°C and in liquid nitrogen, 539 respectively, until use.

540

541 Human subjects

542 No specific criteria such as number of patients (sample size), clinical or demographic were used 543 for inclusion, beyond PCR confirmed SARS-CoV-2 infection in adults.

544

545 Plasma and antibodies

546 Plasma from SARS-CoV-2 naïve and PI donors were collected, heat-inactivated for 1 hour at 547 56°C and stored at -80°C until ready to use in subsequent experiments. Plasma from uninfected 548 donors collected before the pandemic were used as negative controls and used to calculate the 549 seropositivity threshold in our ELISA, cell-based ELISA, ADCC and flow cytometry assays (see 550 below). The RBD-specific monoclonal antibody CR3022 was used as a positive control in our 551 ELISA, cell-based ELISA, and flow cytometry assays and was previously described (Anand et al., 552 2020; Beaudoin-Bussières et al., 2020; Meulen et al., 2006; Prévost et al., 2020). Horseradish 553 peroxidase (HRP)-conjugated Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA; 554 Jackson ImmunoResearch Laboratories) or specific for the Fc region of human IgG (Invitrogen), 555 the Fc region of human IgM (Jackson ImmunoResearch Laboratories) or the Fc region of human 556 IgA (Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect Ab binding 557 in ELISA and cell-based ELISA experiments. Alexa Fluor-647-conjugated goat anti-human Abs 558 able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories) 559 were used as secondary Ab to detect plasma binding in flow cytometry experiments.

560

561 Cell lines

562 293T human embryonic kidney and HOS cells (obtained from ATCC) were maintained at 37°C under 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal 563 bovine serum (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). CEM.NKr CCR5+ 564 565 cells (NIH AIDS reagent program) were maintained at 37°C under 5% CO₂ in Roswell Park 566 Memorial Institute (RPMI) 1640 medium (Gibco) containing 10% FBS and 100 µg/ml of penicillin-567 streptomycin. 293T-ACE2 cell line was previously reported (Prévost et al., 2020). HOS and 568 CEM.NKr CCR5+ cells stably expressing the SARS-CoV-2 S glycoproteins were previously 569 reported (Anand et al., 2021).

570

571 METHOD DETAILS

572 Plasmids

The plasmids expressing the human coronavirus Spike glycoproteins of SARS-CoV-2, SARS-CoV-1 (Hoffmann et al., 2013, 2020), HCoV-OC43 (Prévost et al., 2020) and MERS-CoV (Park et al., 2016) were previously reported. The HCoV-HKU1 S expressing plasmid was purchased from Sino Biological. The plasmids encoding the different SARS-CoV-2 Spike variants (D614G, B.1.1.7, B.1.351, P.1, B.1.526 and B.1.617.2) were previously described (Beaudoin-Bussières et al., 2020; Gong et al., 2021; Li et al., 2021; Tauzin et al., 2021).

579

580 Protein expression and purification

581 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density 582 of 1 x 10^6 cells/mL at 37°C with 8 % CO₂ with regular agitation (150 rpm). Cells were transfected 583 with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussières et al., 2020) using 584 ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week 585 later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo 586 Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as 587 directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against

It is made available under a CC-BY-NC-ND 4.0 International license .

588 phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess 589 purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

- 590
- 591
- 592

593 Enzyme-Linked Immunosorbent Assay (ELISA)

594 The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussières et al., 595 2020: Prévost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 µg/ml), or 596 bovine serum albumin (BSA) (2.5 µg/ml) as a negative control, were prepared in PBS and were 597 adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked 598 with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween20 and 2% BSA) for 1h at 599 room temperature. Wells were then washed four times with washing buffer (Tris-buffered saline 600 [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml) or a 1/250 dilution of plasma were 601 prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the RBD-coated 602 wells for 90 minutes at room temperature. Plates were washed four times with washing buffer 603 followed by incubation with secondary Abs (diluted in a diluted solution of blocking buffer (0.4% 604 BSA)) for 1h at room temperature, followed by four washes. HRP enzyme activity was determined 605 after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer 606 Life Sciences). Light emission was measured with a LB942 TriStar luminometer (Berthold 607 Technologies). Signal obtained with BSA was subtracted for each plasma and was then 608 normalized to the signal obtained with CR3022 present in each plate. The seropositivity threshold 609 was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative 610 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

611

612 Cell-Based ELISA

It is made available under a CC-BY-NC-ND 4.0 International license .

613 Detection of the trimeric SARS-CoV-2 S at the surface of HOS cells was performed by a 614 previously-described cell-based enzyme-linked immunosorbent assay (ELISA) (Anand et al., 615 2021). Briefly, parental HOS cells or HOS-Spike cells were seeded in 96-well plates (4×10⁴ cells 616 per well) overnight. Cells were blocked with blocking buffer (10 mg/ml nonfat dry milk, 1.8 mM 617 CaCl₂, 1 mM MgCl₂, 25 mM Tris [pH 7.5], and 140 mM NaCl) for 30 min. CR3022 mAb (1 µg/ml) 618 or plasma (at a dilution of 1/250) were prepared in blocking buffer and incubated with the cells for 619 1h at room temperature. Respective HRP-conjugated Abs were then incubated with the samples 620 for 45 min at room temperature. For all conditions, cells were washed 6 times with blocking buffer 621 and 6 times with washing buffer (1.8 mM CaCl₂, 1 mM MgCl₂, 25 mM Tris [pH 7.5], and 140 mM 622 NaCI). HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning 623 oxidizing and luminol reagents (PerkinElmer Life Sciences). Light emission was measured with 624 an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with parental HOS was 625 subtracted for each plasma and was then normalized to the signal obtained with CR3022 mAb 626 present in each plate. The seropositivity threshold was established using the following formula: 627 mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-628 pandemic SARS-CoV-2 negative plasma).

629

630 **Cell surface staining and flow cytometry analysis**

631 293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination 632 with plasmids encoding the full-length Spikes of SARS-CoV-2 variants or Spikes from different 633 Betacoronaviruses. 48h post-transfection, S-expressing cells were stained with the CV3-25 Ab 634 (Jennewein et al., 2021) or plasma (1/250 dilution). AlexaFluor-647-conjugated goat anti-human 635 IgM+IgG+IgA Abs (1/800 dilution) were used as secondary Abs. The percentage of transfected 636 cells (GFP+ cells) was determined by gating the living cell population based on viability dye 637 staining (Agua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences) 638 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The seropositivity threshold

It is made available under a CC-BY-NC-ND 4.0 International license .

was established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative
plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma). The
conformational-independent S2-targeting mAb CV3-25 was used to normalize Spike expression.
CV3-25 was shown to effectively recognize all SARS-CoV-2 Spike variants (Li et al., 2021).

643

644 ADCC assay

645 This assay was previously described (Anand et al., 2021). For evaluation of anti-SARS-CoV-2 antibody-dependent cellular cytotoxicity (ADCC), parental CEM.NKr CCR5+ cells were mixed at 646 647 a 1:1 ratio with CEM.NKr cells stably expressing a GFP-tagged full length SARS-CoV-2 Spike 648 (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained for viability (AquaVivid; Thermo 649 Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell proliferation dye eFluor670; Thermo 650 Fisher Scientific) to be used as target cells. Overnight rested PBMCs were stained with another 651 cellular marker (cell proliferation dye eFluor450: Thermo Fisher Scientific) and used as effector 652 cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates. 653 Plasma (1/500 dilution) or monoclonal antibody CR3022 (1 µg/mL) were added to the appropriate 654 wells. The plates were subsequently centrifuged for 1 min at 300g, and incubated at 37°C, 5% 655 CO₂ for 5 hours before being fixed in a 2% PBS-formaldehyde solution. ADCC activity was 656 calculated using the formula: [(% of GFP+ cells in Targets plus Effectors) - (% of GFP+ cells in 657 Targets plus Effectors plus plasma/antibody)]/(% of GFP+ cells in Targets) x 100 by gating on 658 transduced live target cells. All samples were acquired on an LSRII cytometer (BD Biosciences) 659 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The specificity threshold was 660 established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative plasma + 661 (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

662

663 Virus neutralization assay

It is made available under a CC-BY-NC-ND 4.0 International license .

664 To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-665 Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein (D614G, B.1.1.7, P.1, B.1.351, B.1.617.2, B.1.526 and SARS-CoV) at a ratio of 10:1. Two days 666 667 post-transfection, cell supernatants were harvested and stored at -80°C until use. For the 668 neutralization assay, 293T-ACE2 target cells were seeded at a density of 1×10⁴ cells/well in 96-669 well luminometer-compatible tissue culture plates (Perkin Elmer) 24h before infection. 670 Pseudoviral particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 671 1/31250) for 1h at 37°C and were then added to the target cells followed by incubation for 48h at 672 37°C. Then, cells were lysed by the addition of 30 µL of passive lysis buffer (Promega) followed 673 by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to 674 measure the luciferase activity of each well after the addition of 100 µL of luciferin buffer (15mM 675 MgSO₄, 15mM KPO₄ [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin 676 potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID₅₀) represents the 677 plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

678

679 SARS-CoV-2-specific B cells characterization

680 To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa 681 Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's protocol. 682 Approximately 2×10⁶ frozen PBMCs from SARS-CoV-2 naïve and prior infection donors were 683 prepared in Falcon® 5ml-round bottom polystyrene tubes at a final concentration of 684 4x10⁶ cells/mL in RPMI 1640 medium (GIBCO) supplemented with 10% of fetal bovine serum (Seradiom), Penicillin- Streptomycin (GIBCO) and HEPES (GIBCO). After a rest of 2h at 37°C 685 686 and 5% CO₂, cells were stained using Aquavivid viability marker (Biosciences) in DPBS (GIBCO) 687 at 4°C for 20 min. The detection of SARS-CoV-2-antigen specific B cells was done by adding the 688 RBD probes to the antibody cocktail (IgM BUV737, CD24 BUV805, IgG BV421, CD3 BV480,

It is made available under a CC-BY-NC-ND 4.0 International license .

CD56 BV480, CD14 BV480, CD16 BV480, CD20 BV711, CD21 BV786, HLA DR BB700, CD27
APC R700; CD19 BV650, CD38 BB790, CD138 BUV661, CCR10 BUV395, IgD BUV563 and IgA
PE). Staining was performed at 4°C for 30 min and cells were fixed using 1% paraformaldehyde
(Sigma-Aldrich) at 4°C for 15 min. Stained PBMC samples were acquired on FACSymphony[™]
A5 Cell Analyzer (BD Biosciences) and analyzed using FlowJo v10.7.1 software.

694

695 QUANTIFICATION AND STATISTICAL ANALYSIS

696 Statistical analysis

697 Symbols represent biologically independent samples from SARS-CoV-2 naïve individuals or 698 SARS-CoV-2 PI individuals. Lines connect data from the same donor. Statistics were analyzed 699 using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Every dataset was tested for 700 statistical normality and this information was used to apply the appropriate (parametric or 701 nonparametric) statistical test. Differences in responses for the same patient before and after 702 vaccination were performed using Kruskal-Wallis tests. Differences in responses between naïve 703 and PI individuals at each time point were measured by Mann-Whitney (V0, V1 and V2) or 704 Kruskal-Wallis (V3) tests. Differences in responses against the different Spikes for the same 705 patient were measured by Friedman tests. P values < 0.05 were considered significant; 706 significance values are indicated as * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.001. 707 Spearman's R correlation coefficient was applied for correlations. Statistical tests were two-sided 708 and p < 0.05 was considered significant.

709

710 Software scripts and visualization

Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph,

tidyverse, and RColorBrewer packages (R; R studio). Edges are only shown if p < 0.05, and nodes

It is made available under a CC-BY-NC-ND 4.0 International license .

- 713 are sized according to the connecting edges' r values. Nodes are color-coded according to groups
- of parameters.
- 715
- 716 SUPPLEMENTAL INFORMATION
- 717 Supplemental information can be found online at ...

It is made available under a CC-BY-NC-ND 4.0 International license .

718 **REFERENCES**

- Allen, H., Vusirikala, A., Flannagan, J., Twohig, K.A., Zaidi, A., Groves, N., Lopez-Bernal, J.,
 Harris, R., Charlett, A., Dabrera, G., et al. (2021). Increased Household Transmission of COVID19 Cases Associated with SARS-CoV-2 Variant of Concern B.1.617.2: A national case-control
 study,
- 723 https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+C
- 724 OVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa. 21.

Anand, S.P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M.-J.,
Lewin, A., Bazin, R., and Finzi, A. (2020). High-throughput detection of antibodies targeting the
SARS-CoV-2 Spike in longitudinal convalescent plasma samples (Microbiology).

Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard,
N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of humoral
immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months postsymptom onset. Cell Rep. Med. 100290.

- Annavajhala, M.K., Mohri, H., Wang, P., Nair, M., Zucker, J.E., Sheng, Z., Gomez-Simmonds, A.,
 Kelley, A.L., Tagliavia, M., Huang, Y., et al. (2021a). Emergence and Expansion of the SARS-
- CoV-2 Variant B.1.526 Identified in New York. medRxiv 2021.02.23.21252259.

Annavajhala, M.K., Mohri, H., Wang, P., Nair, M., Zucker, J.E., Sheng, Z., Gomez-Simmonds, A.,
Kelley, A.L., Tagliavia, M., Huang, Y., et al. (2021b). A Novel and Expanding SARS-CoV-2
Variant, B.1.526, Identified in New York. MedRxiv 2021.02.23.21252259.

Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector,
S.A., Rouphael, N., Creech, C.B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARSCoV-2 Vaccine. N. Engl. J. Med. *384*, 403–416.

Beaudoin-Bussières, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,
Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral Responses
against SARS-CoV-2 Spike in Convalescent Individuals. MBio *11*.

Beaudoin-Bussieres, G., Chen, Y., Ullah, I., Prevost, J., Tolbert, W.D., Symmes, K., Ding, S.,
Benlarbi, M., Gong, S.Y., Tauzin, A., et al. (2021). An anti-SARS-CoV-2 non-neutralizing antibody
with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18hACE2 mice (Microbiology).

Brown, K.A., Tibebu, S., Daneman, N., Schwartz, K., Whelan, M., and Buchan, S. (2021).
Comparative Household Secondary Attack Rates associated with B.1.1.7, B.1.351, and P.1
SARS-CoV-2 Variants. medRxiv 2021.06.03.21258302.

751 CDC (2021). Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC, 752 https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

Collier, D.A., De Marco, A., Ferreira, I.A.T.M., Meng, B., Datir, R.P., Walls, A.C., Kemp, S.A.,
Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA
vaccine-elicited antibodies. Nature 1–10.

Dagpunar, J. (2021). Interim estimates of increased transmissibility, growth rate, and reproduction
 number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. medRxiv
 2021.06.03.21258293.

Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I.,
Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8
months after infection. Science eabf4063.

Davies, N.G., Barnard, R.C., Jarvis, C.I., Kucharski, A.J., Munday, J., Pearson, C.A.B., Russell,
T.W., Tully, D.C., Abbott, S., Gimma, A., et al. (2020). Estimated transmissibility and severity of
novel SARS-CoV-2 Variant of Concern 202012/01 in England. MedRxiv 2020.12.24.20248822.

Davies, N.G., Abbott, S., Barnard, R.C., Jarvis, C.I., Kucharski, A.J., Munday, J.D., Pearson,
C.A.B., Russell, T.W., Tully, D.C., Washburne, A.D., et al. (2021). Estimated transmissibility and
impact of SARS-CoV-2 lineage B.1.1.7 in England. Science *372*.

Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. *20*, 533–534.

Doria-Rose, N., Suthar, M.S., Makowski, M., O'Connell, S., McDermott, A.B., Flach, B.,
Ledgerwood, J.E., Mascola, J.R., Graham, B.S., Lin, B.C., et al. (2021). Antibody Persistence
through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N. Engl. J. Med.
384, 2259–2261.

ECDC (2021). Risk of spread of new SARS-CoV-2 variants of concern in the EU/EEA - first
 update, https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf. 29.

Efrati, S., Catalogna, M., Abu Hamad, R., Hadanny, A., Bar-Chaim, A., Benveniste-Levkovitz, P.,
and Levtzion-Korach, O. (2021). Safety and humoral responses to BNT162b2 mRNA vaccination
of SARS-CoV-2 previously infected and naive populations. Sci. Rep. *11*, 16543.

Fisman, D.N., and Tuite, A.R. (2021). Progressive Increase in Virulence of Novel SARS-CoV-2
Variants in Ontario, Canada. medRxiv 2021.07.05.21260050.

Fraley, E., LeMaster, C., Banerjee, D., Khanal, S., Selvarangan, R., and Bradley, T. (2021).
Cross-reactive antibody immunity against SARS-CoV-2 in children and adults. Cell. Mol. Immunol. *18*, 1826–1828.

Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A.,
Jankovic, M., Schaefer-Babajew, D., Oliveira, T.Y., et al. (2021). Evolution of antibody immunity
to SARS-CoV-2. Nature.

Gilbert, P.B., Montefiori, D.C., McDermott, A., Fong, Y., Benkeser, D., Deng, W., Zhou, H.,
Houchens, C.R., Martins, K., Jayashankar, L., et al. (2021). Immune Correlates Analysis of the
mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv 2021.08.09.21261290.

Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen,
K.A., Reynaldi, A., Khoury, D.S., Pattekar, A., et al. (2021a). mRNA Vaccination Induces Durable
Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. bioRxiv
2021.08.23.457229.

Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S.,
Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021b). Distinct antibody and memory B cell
responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci.
Immunol. 6.

Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L., Haas, E.J., Milo, R.,
Alroy-Preis, S., Ash, N., and Huppert, A. (2021). Waning immunity of the BNT162b2 vaccine: A
nationwide study from Israel. medRxiv 2021.08.24.21262423.

Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D.,
Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to selected
SARS-CoV-2 emerging variants Spike antigenicity. bioRxiv 2021.08.04.455140.

Hicks, J., Klumpp-Thomas, C., Kalish, H., Shunmugavel, A., Mehalko, J., Denson, J.-P., Snead,
K., Drew, M., Corbett, K., Graham, B., et al. (2020). Serologic cross-reactivity of SARS-CoV-2
with endemic and seasonal Betacoronaviruses. MedRxiv 2020.06.22.20137695.

Hoffmann, M., Müller, M.A., Drexler, J.F., Glende, J., Erdt, M., Gützkow, T., Losemann, C., Binger,
T., Deng, H., Schwegmann-Weßels, C., et al. (2013). Differential sensitivity of bat cells to infection
by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses.
PloS One *8*, e72942.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens,
T.S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2
and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell *181*, 271-280.e8.

Isabel, S., Graña-Miraglia, L., Gutierrez, J.M., Bundalovic-Torma, C., Groves, H.E., Isabel, M.R.,
Eshaghi, A., Patel, S.N., Gubbay, J.B., Poutanen, T., et al. (2020). Evolutionary and structural
analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci. Rep.
10, 14031.

Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N.,
McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al. (2020). An mRNA Vaccine
against SARS-CoV-2 — Preliminary Report. N. Engl. J. Med. 383, 1920–1931.

JCVI (2021). Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary
 dose vaccination, https://www.gov.uk/government/publications/third-primary-covid-19-vaccine dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and immunisation-jcvi-advice-on-third-primary-dose-vaccination.

Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K., Seydoux,
E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and Characterization of CrossNeutralizing Coronavirus Antibodies from COVID-19+ Subjects. bioRxiv 2021.03.23.436684.

Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,
Anand, S.P., et al. (2021). Structural Basis and Mode of Action for Two Broadly Neutralizing
Antibodies Against SARS-CoV-2 Emerging Variants of Concern. BioRxiv Prepr. Serv. Biol.
2021.08.02.454546.

Lozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., Del Pino-Molina, L., Bravo-Gallego, L.Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., et al. (2021). Differential effects

- of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19
 recovered individuals. Cell Rep. 109570.
- Meulen, J. ter, Brink, E.N. van den, Poon, L.L.M., Marissen, W.E., Leung, C.S.W., Cox, F.,
 Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., Deventer, E. van, et al. (2006). Human Monoclonal
 Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.
 PLOS Med. *3*, e237.
- Moore, J.P., and Klasse, P.J. (2020). COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. J. Virol. *94*.
- Muruato, A.E., Fontes-Garfias, C.R., Ren, P., Garcia-Blanco, M.A., Menachery, V.D., Xie, X., and Shi, P.-Y. (2020). A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. *11*, 4059.
- Ng, K.W., Faulkner, N., Cornish, G.H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C.,
 Wrobel, A.G., Benton, D.J., et al. (2020). Preexisting and de novo humoral immunity to SARSCoV-2 in humans. Science *370*, 1339–1343.
- Painter, M.M., Mathew, D., Goel, R.R., Apostolidis, S.A., Pattekar, A., Kuthuru, O., Baxter, A.E.,
 Herati, R.S., Oldridge, D.A., Gouma, S., et al. (2021). Rapid induction of antigen-specific CD4+ T
 cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2
 mRNA vaccination. Immunity S1074761321003083.
- Park, J.-E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray, P.B., and Gallagher, T. (2016).
 Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus
 tropism. Proc. Natl. Acad. Sci. *113*, 12262–12267.
- Parry, H., Bruton, R., Stephens, C., Brown, K., Amirthalingam, G., Otter, A., Hallis, B., Zuo, J.,
 and Moss, P. (2021). Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after
 extended-interval homologous dual vaccination in older people. Immun. Ageing A *18*, 34.
- Pearson, C.A.B., Russell, T.W., Davies, N.G., Kucharski, A.J., CMMID COVID-19 working group,
 Edmunds, W.J., and Eggo, R.M. (2021). Estimates of severity and transmissibility of novel SARSCoV-2 variant 501Y.V2 in South Africa, https://cmmid.github.io/topics/covid19/sa-novelvariant.html.
- Pilishvili, T. (2021). Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna
 COVID-19 Vaccines Among Health Care Personnel 33 U.S. Sites, January–March 2021.
 MMWR Morb. Mortal. Wkly. Rep. *70*.
- Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais,
 C., Porrot, F., Robillard, N., Puech, J., et al. (2021a). Reduced sensitivity of SARS-CoV-2 variant
 Delta to antibody neutralization. Nature *596*, 276–280.
- Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C.,
 Buchrieser, J., Rajah, M.M., Bishop, E., et al. (2021b). Sensitivity of infectious SARS-CoV-2
 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917–924.

- 872 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
- Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA
 Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615.
- 875 Prévost, J., and Finzi, A. (2021). The great escape? SARS-CoV-2 variants evading neutralizing 876 responses. Cell Host Microbe *29*, 322–324.
- Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand,
 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral
 Responses against SARS-CoV-2 Spike. Cell Rep. Med. *1*, 100126.
- Prévost, J., Richard, J., Gasser, R., Ding, S., Fage, C., Anand, S.P., Adam, D., Vergara, N.G.,
 Tauzin, A., Benlarbi, M., et al. (2021). Impact of temperature on the affinity of SARS-CoV-2 Spike
 glycoprotein for host ACE2. J. Biol. Chem. 101151.
- Puranik, A., Lenehan, P.J., Silvert, E., Niesen, M.J.M., Corchado-Garcia, J., O'Horo, J.C., Virk,
 A., Swift, M.D., Halamka, J., Badley, A.D., et al. (2021). Comparison of two highly-effective mRNA
 vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.
- R R: a language and environment for statistical computing. https://www.gbif.org/fr/tool/81287/r-a language-and-environment-for-statistical-computing.
- 888 R studio RStudio | Open source & professional software for data science teams. 889 https://rstudio.com/.
- Rabaan, A.A., Al-Ahmed, S.H., Haque, S., Sah, R., Tiwari, R., Malik, Y.S., Dhama, K., Yatoo,
 M.I., Bonilla-Aldana, D.K., and Rodriguez-Morales, A.J. (2020). SARS-CoV-2, SARS-CoV, and
 MERS-COV: A comparative overview. Infez. Med. *28*, 174–184.
- Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock,
 T., Robertson, D.L., and Volz, E. (2020). Preliminary genomic characterisation of an emergent
 SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations SARS-CoV-2
 coronavirus / nCoV-2019 Genomic Epidemiology.
- Sabino, E.C., Buss, L.F., Carvalho, M.P.S., Prete, C.A., Crispim, M.A.E., Fraiji, N.A., Pereira,
 R.H.M., Parag, K.V., Peixoto, P. da S., Kraemer, M.U.G., et al. (2021). Resurgence of COVID-19
 in Manaus, Brazil, despite high seroprevalence. The Lancet *397*, 452–455.
- Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal,
 K., Quandt, J., Maurus, D., et al. (2020). COVID-19 vaccine BNT162b1 elicits human antibody
 and T H 1 T cell responses. Nature *586*, 594–599.
- Sarkar, J.P., Saha, I., Seal, A., Maity, D., and Maulik, U. (2021). Topological Analysis for
 Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19
 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV. Infect. Genet. Evol. *88*,
 104708.
- Skowronski, D., and De Serres, G. (2021). Safety and Efficacy of the BNT162b2 mRNA Covid-19
 Vaccine. N. Engl. J. Med. NEJMc2036242.

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M.,
Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts crossvariant neutralizing antibodies elicited by SARS-CoV-2 infection. Science eabg9175.

Tang, J.W., Toovey, O.T.R., Harvey, K.N., and Hui, D.S.C. (2021). Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J. Infect. *8*2, e8–e10.

Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., Frankland,
T.B., Ogun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Six-Month Effectiveness of BNT162B2
mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study
(Rochester, NY: Social Science Research Network).

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussières, G., Brassard,
N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine
BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe
0.

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D.,
Pillay, S., San, E.J., Msomi, N., et al. (2020). Emergence and rapid spread of a new severe acute
respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations
in South Africa. MedRxiv 2020.12.21.20248640.

Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussières, G.,
Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice
reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity S10747613(21)00347-2.

Urbanowicz, R.A., Tsoleridis, T., Jackson, H.J., Cusin, L., Duncan, J.D., Chappell, J.G., Tarr,
A.W., Nightingale, J., Norrish, A.R., Ikram, A., et al. (2021). Two doses of the SARS-CoV-2
BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2
2 infection. Sci. Transl. Med. eabj0847.

Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon,
D.J., Dabrera, G., O'Toole, Á., et al. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7 in
England: Insights from linking epidemiological and genetic data. MedRxiv 2020.12.30.20249034.

Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P.,
Hatipoglu, E., Ngai, Y., et al. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs
B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet *397*, 2331–2333.

Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure,
Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell *181*, 281-292.e6.

Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong,
P.D., et al. (2021a). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H.H., Barnes, C.O., Cipolla, M., Ramos, V., et al. (2021b). Naturally enhanced neutralizing breadth
against SARS-CoV-2 one year after infection. Nature *595*, 426–431.

It is made available under a CC-BY-NC-ND 4.0 International license .

947 WHO (2021). Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine,

- 948 BNT162b2, under Emergency Use Listing, https://www.who.int/publications/i/item/WHO-2019-949 nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1.
- 950 World Health Organization WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int.



Figure 1

Naïve (2 doses, long interval) It in a reviews ly infected (2 doses, long interval) se
 Previously infected (1 dose)



• Naïve (2 doses, long interval)

Previously infected (2 doses, long interval) Previously infected (1 dose)

Β

Veutralization (ID₅₀)

VO V1







• V3

V2

Neutralization D614G VO V1 V2 V3

Figure 3

• Previously infected (1 dose)





Figure 5



Parameters

ADCC

8 B cells

. Binding

R FACS

Neut

r values

- 10

- 0.5

- - 0.0

- -0.5

-1.0

• 0.2

strength

• 0

• 1

● 2 ● 3

Parameters

. ADCC

8 B cells

Binding

. FACS

Neut

r values

1.0

- - 0.0

- - -0.5

- -1.0

alpha

• 0.2

strength

• 4

6

810

Demographics

alpha

Demographics





Figure 6

- Naïve (2 doses, long interval)
- Previously infected (1 dose)

- Previously infected (2 doses, long interval)
- Naïve (2 doses, short interval)



Figure S1 : Recognition of SARS-CoV-2 Spike variants and *hCoronaviruses* Spike by plasma from naïve and PI donors at each time point, Related to Figure 2 and 5.

293T cells were transfected with the indicated Betacoronavirus Spike and stained with the CV3-25 Ab or with plasma collected at V0 (**A**), V1 (**B**), V2 (**C**) and V3 (**D**) and analyzed by flow cytometry. Plasma recognitions are normalized with CV3-25 binding. Naïve and PI donors with a long interval between the two doses are represented by red and black points respectively, PI donors who received just one dose by blue points and naïve donors with a short interval between the two doses by green points. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant).

- Naïve (2 doses, long interval)
- Previously infected (1 dose)

- Previously infected (2 doses, long interval)
- Naïve (2 doses, short interval)



Figure S2 : Neutralization of SARS-CoV-2 Spike variants and SARS-CoV-1 Spike by plasma from naïve and PI donors at each time point, Related to Figures 3, 4 and 5.

Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S variant or SARS-CoV-1 S glycoproteins, with serial dilutions of plasma collected at V0 (**A**), V1 (**B**), V2 (**C**) and V3 (**D**) for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID50) values were determined using a normalized non-linear regression using GraphPad Prism software. Naïve and PI donors with a long interval between the two doses are represented by red and black points respectively, PI donors who received just one dose by blue points and naïve donors with a short interval between the two doses by green points. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means \pm SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.001; ns, non-significant).